<DOC>
	<DOCNO>NCT00004906</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity response rate induction therapy docetaxel doxorubicin woman chemotherapy naive metastatic breast cancer . II . Assess toxicity response rate sequential high dose chemotherapy follow induction chemotherapy woman metastatic breast cancer . III . Determine hematopoietic recovery rate follow CD34+ select peripheral blood stem cell support patient population . IV . Assess toxicity noncytotoxic maintenance therapy follow high dose chemotherapy patient population . OUTLINE : This multicenter study . Patients prior chemotherapy metastatic disease receive induction chemotherapy consist doxorubicin IV immediately follow docetaxel IV 1 hour day 1 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SQ ) begin day 2 continue day 11-15 . Induction therapy repeat every 3 week 4 course . Within 4 week last course induction chemotherapy , patient receive mobilization chemotherapy consist cyclophosphamide IV 2 day , etoposide IV cisplatin IV 3 day . At 24 hour follow completion chemotherapy , patient receive G-CSF SQ twice daily target number peripheral blood stem cell ( PBSC ) reach . Within 5 week follow completion mobilization chemotherapy , patient receive cyclophosphamide IV , thiotepa IV , carboplatin IV continuously day -7 -4 . Patients receive CD34+ select PBSC day 0 follow 4 hour later G-CSF SQ daily continue blood count recover . Within 30 day blood count recovery immediately follow completion post transplantation radiotherapy , patient receive maintenance therapy consist oral anastrozole daily disease progression . Patients bone involvement also receive pamidronate IV 2 hour monthly 1 year . Patients follow monthly 6 month , every 3 month 1 year , every 4-6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Pamidronate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epithelial carcinoma breast Metastatic disease include ipsilateral supraclavicular lymph node chest wall ( axillary node ) Measurable evaluable ( bone ) disease exam radiography No apocrine , adenocystic , squamous cell carcinoma , sarcoma , lymphoma No symptomatic CNS disease clinical evidence CNS metastases Surgically accessible disease Hormone receptor status : Progesterone estrogen receptor status know PATIENT CHARACTERISTICS : Age : 18 65 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 3.0 mg/dL SGOT great 6 time upper limit normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : Ejection fraction least 40 % MUGA scan No angina pectoris require active nitrate therapy No myocardial infarction within past 6 month No uncontrolled congestive heart failure No uncontrolled hypertension No major ventricular arrhythmia Other : No uncompensated endocrine dysfunction HIV negative Hepatitis B negative ( core antigen negative vaccinate ) No prior malignancy within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix No active infection medical condition would preclude study Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 6 month since prior adjuvant therapy Biologic therapy : Not specify Chemotherapy : No 2 course prior induction docetaxel doxorubicin allow stag within 4 week chemotherapy initiation No prior cumulative adjuvant doxorubicin dose great 360 mg/m2 No prior chemotherapy metastatic disease Endocrine therapy : Prior hormonal therapy metastatic disease allow Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>